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The N-terminal ATP binding domain of the DNA gyrase B subunit is a validated drug target for
antibacterial drug discovery. Structural information for this domain (pGyrB) from Pseudomonas
aeruginosa is still missing. In this study, the interaction between pGyrB and a bis-pyridylurea inhi-
bitor was characterized using several biophysical methods. We further carried out structural anal-
ysis of pGyrB using NMR spectroscopy. The secondary structures of free and inhibitor bound pGyrB
were obtained based on backbone chemical shift assignment. Chemical shift perturbation and NOE
experiments demonstrated that the inhibitor binds to the ATP binding pocket. The results of this
study will be helpful for drug development targeting P. aeruginosa.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The bacterial genome encodes two types of topoisomerases, I
and II which differ in the mechanism of DNA strand breakage [1].
The type II topoisomerases consist of two types, DNA gyrase and
topoisomerase IV (TopoIV). These enzymes play essential roles in
DNA replication by managing the topological states of DNA in
the cell [2,3]. In prokaryotes, type II topoisomerases consist of
two subunits and are functional in tetrameric form, which is differ-
ent from the eukaryotic type II topoisomerases that exist as
homodimers [3]. Prokaryotic DNA gyrase contains two gyrase A
(GyrA) and gyrase B (GyrB) subunits respectively to form the
heterotetramer. For Escherichia coli (E. coli), GyrA is a 97kDa protein
that is involved in DNA binding and GyrB, it is a 90kDa protein with
an N-terminal ATP binding domain [4].
Interfering with bacterial DNA replication by targeting type II
topoisomerases has been shown to be an efficient strategy to
develop antibacterial agents [5]. Successful examples include thefluoroquinolone class of antibiotics [6]. Many other novel and
potent inhibitors have been developed in recent years [7]. The
N-terminal domain of the type II topoisomerases contains the ATP
binding pocket and has been of great interest in drug development
because this domain exhibited high sequence homology among
pathogenic bacteria and low homology with eukaryotes [5,7].
Structure-based drug design has been demonstrated to be a pow-
erful tool in developing inhibitors targeting both GyrB and
TopolV ATP binding domains. Several classes of inhibitors have
been discovered using this approach [8–11].
The structures of the N-terminal ATP binding domains of both
GyrB and E subunit of TopoIV (ParE) from E. coli have been reported
[12,13]. The structures of GyrB/ParE and inhibitor complexes
demonstrated that most of the inhibitors are binding with the
ATP binding pocket [9]. Although the structure of this domain is
similar among the type II topoisomerases, a single residue differ-
ence among different topoisomerases can result in different inhibi-
tor potency [2]. Understanding protein-inhibitor interactions will
provide useful information in the drug development process.
NMR spectroscopy has been proven to be a useful tool in drug
development [14]. Despite the extensive X-ray studies of GyrBs
and ParEs, few NMR studies have been conducted for the
N-terminal domain of GyrB and ParE from bacteria except for the
Fig. 1. NMR spectra of pGyrB. (A) 1H–15N-TROSY spectra of pGyrB. The NMR spectra of pGyrB in the absence (black) and presence (red) of the inhibitor were collected and
superimposed, and two peaks that undergo significant shifts upon complex formation are highlighted. Inside spectra are selected regions of spectra with inhibitor/protein
ratios of 0 (black), 0.5 (green) and 1 (red), respectively. The interaction is undergoing slow exchange. (B) 3D-HNCACB of pGyrB in the absence and presence of the inhibitor.
Select strips of HNCACB spectrum for several residues are shown. Upper and lower panels are free and inhibitor-bound pGyrB, respectively. The peaks are labeled with residue
number and atom types.
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N-terminal 24kDa fragment of GyrB from E. coli [15,16].
In this study, we obtained the N-terminal 24kDa domain of the
GyrB from Pseudomonas aeruginosa (P. aeruginosa) (referred as
pGyrB) for NMR studies. As the structure of this domain is not
available, structural information for this domain will be useful
for structure-based drug design because P. aeruginosa is an impor-
tant pathogenic species. We managed to obtain the backbone
assignments for both free and inhibitor-bound forms of pGyrB.
The secondary structure and dynamic property of pGyrB in solu-
tion were analyzed and the bis-pyridylurea inhibitor was shown
to bind to the ATP binding pocket.
2. Materials and methods
2.1. Sample preparation
The cDNA encoding the pGyrB was amplified by polymerase
chain reaction using genomic DNA of P. aeruginosa as a template
and cloned into NdeI and XhoI sites of pET29b. The resulting plas-
mid can express residues 1–222 of GyrB and extra 8 residues
(LEHHHHHH) at the C-terminus. To express pGyrB from E. coli,
the plasmid was transformed in E. coli (BL21DE3) competent cells.
The recombinant protein was expressed and purified using affinity
purification and gel filtration chromatography [17,18]. Briefly, sev-
eral colonies were picked up from the plate and inoculated in
20 mL of M9 medium. The overnight culture at 37 C was then
transferred into 1 L of M9 medium. The recombinant protein was
induced for 18 h at 18 C by adding b-D-1-thiogalactopyranoside
(IPTG) to 1 mM. The E. coli cells were harvested by centrifugation
and the recombinant protein was purified in a buffer that con-
tained 20 mM sodium phosphate, pH 6.5, 80 mM KCl, 2 mM DTT
and 0.5 mM EDTA. A triple-labeled sample (13C, 15N and 2H) was
prepared by growing E. coli in a M9 medium that contained 1 g/L
15NH4Cl, 2 g/L 2H-13C-glucose and D2O (99.9%). Purified protein
was concentrated to 0.5–0.8 mM for further studies.2.2. Backbone resonance assignment
Uniformly 15N- and 13C/15N/2H-labeled proteins were used in
NMR data acquisition. Two- (2D) and three-dimensional (3D)
experiments and transverse relaxation-optimized spectroscopy
(TROSY) [19,20]-based experiments including HSQC, HNCACB,
HNCOCACB, HNCOCA, HNCA, HNCACO and HNCO were collected
and processed. For pGyrB and inhibitor complex, protein was first
purified and inhibitor was then added into the solution to a pro-
tein: inhibitor molar ratio of 1:1.2. Inhibitor was synthesized and
purified as described [21]. All the experiments were conducted at
25 C on a Bruker Avance 700 spectrometer equipped with a cry-
oprobe. All the spectra were processed using NMRPipe [22] or
Topspin 2.1 and analyzed using NMRView [23] and CARA (http://
www.mol.biol.ethz.ch/groups/wuthrich_group). The secondary
structure was analyzed using TALOS+ based on the backbone
chemical shifts [24].
2.3. Protein-inhibitor interactions
1H–15N-HSQC spectra of pGyrB in the absence and presence of
the inhibitor were compared and chemical shift perturbations
(CSP) were monitored [25]. The combined chemical shift changes
(Dd) were calculated using the following equation. Dd =
((DdHN)2 + (DdN/5)2)0.5, where DdHN is the chemical shift changes
upon inhibitor binding in the amide proton dimension and DdN is
the chemical shift changes in the amide dimension [25]. To obtain
protein-inhibitor inter-molecular NOEs, a NOESY-TROSY experi-
ment with a mixing time of 100 ms was recorded using a sample
that contained 0.5 mM of 13C/15N/2H-labeled pGyrB and 1 mM of
inhibitor.
2.4. Effect of inhibitor on protein thermal stability
Thermal shift experiment was carried out on a Roche LC480 PCR
machine. Each assay well contained 10 lM pGyrB, 20 spyro
Y. Li et al. / FEBS Letters 589 (2015) 2683–2689 2685orange. The assay buffer contained 50 mM HEPES, pH 7.2, 250 mM
NaCl and 5 mM MgCl2.
2.5. Isothermal Titration Calorimetry (ITC) experiment
ITC experiment was performed on an Auto-iTC200 instrument
(Microcal Inc.). The experiment was carried out at 25 C. Protein
was prepared in a buffer that contained 50 mM HEPES, pH 7.5,
250 mM NaCl and 5 mM MgCl2 at concentrations of 100 lM.
Inhibitor was prepared in the same buffer and loaded into the syr-
inge automatically. Titration was carried out with 18 injections
over a period of 40 min with stirring at 1000 rpm.
2.6. Protein relaxation analysis
The 15N longitudinal T1, and transverse T2 relaxation rates and
backbone 1H–15N-heteronuclear NOE (hetNOE) experiments [26]
were collected at 298 K using a purified pGyrB sample in the
absence and presence of the inhibitor at a Bruker Avance
700 MHz magnet. For T1 measurements, the relaxation delays of
100, 300, 500, 1000, 1400, 1800, 2000, 2500 and 3000 ms were
recorded. For T2 measurements, the data were acquired with
delays of 16.9, 34, 51, 68, 85, 102, 119, 136 and 153 ms. The
hetNOE was obtained using two datasets that were collected with
and without initial proton saturation for a period of 3 s. The col-
lected spectra were then processed with NMRPipe [22] and ana-
lyzed with NMRView [23].Fig. 2. TSA and ITC analysis. (A) TSA of pGyrB in the absence and presence of the
inhibitor. Effect of DMSO, different concentrations of inhibitor on the thermal
stability of pGyrB is plotted. (B) ITC of the inhibitor against pGyrB. The binding
constant was 54.6 nM.3. Results
3.1. NMR spectra of pGyrB
Structural studies of GyrB from E. coli revealed that the
N-terminal ATP binding domain contains eight b-strands backed
on the side with several helices [27]. Free pGyrB exhibited well dis-
persed cross peaks in 1H–15N-TROSY spectrum (Fig. 1A), which also
suggested that it constrains b-strands. The OD280/OD260 of purified
protein was approximately 0.6, suggesting that pGyrB sample does
not contain any nucleotides. Protein aggregation was observed
when the sample was kept at room temperature for more than
2 days. Although 3D NMR experiment data were collected for back-
bone assignment, the data quality was not good enough to com-
plete the assignment using the conventional strategy due to the
weak signal in the HNCACB experiment (Fig. 1B). In the presence
of bis-pyridylurea, a potent inhibitor of both ParE and GyrB of
E. coli [21], chemical shift perturbation was observed, suggesting
that pGyrB binds to the inhibitor in solution (Fig. 1A). The
protein-inhibitor complex was stable for more than 7 days and
the quality of the 3D spectra was improved (Fig. 1B), which made
the backbone assignment possible. Both thermal shift assay (TSA)
and ITC were carried out to understand protein-inhibitor interac-
tions. TSA showed that thermal shift (DTm) caused by inhibitor
binding was more than 9 C (Fig. 2A). ITC result suggested that
the binding affinity (KD) was 54.6 nM and reaction stoichiometry
(n) was approximately 1 (Fig. 2B), which explained the interaction
was undergoing slow exchange observed in the NMR study (Fig. 1).
3.2. Backbone assignment of free pGyrB and complex
Backbone resonance assignment for the pGyrB-inhibitor com-
plex was obtained using conventional 3D experiments. The assign-
ments of the 1H–15N-TROSY spectra of pGyrB in the absence and
presence of the inhibitor are shown in Fig. 3A. Most of the back-
bone amides and amide protons were assigned except M1, L100
and V120. Other backbone resonance assignments including Ca(218 of 222), Cb (190 of 198) and C0 (217 of 222) have been
obtained. The assignment of free pGyrB was achieved by referring
to the assignment of the complex. The assignments of free and
inhibitor-bound pGyrB have been deposited in the Biological
Magnetic Resonance Bank (BMRB) with accession numbers 26597
and 26598, respectively. Compared with the 1H–15N-TROSY spec-
trum of free pGyrB, no extra peaks appeared and no line-
broadening was observed in the 1H–15N-TROSY spectrum of the
pGyrB-inhibitor complex because the interaction was undergoing
slow exchange (Figs. 1A and 2).
3.3. Secondary structural analysis of pGyrB and the complex
The secondary structure analysis for pGyrB in the absence and
presence of the inhibitor was conducted using TALOS+ [24]. Both
forms showed similar secondary structural elements to E. coli
Fig. 3. Assignments and secondary structural analysis for pGyrB and its complex. (A and B) Assignment of the 1H–15N-TROSY spectra of pGyrB in the absence (B) and presence
of the inhibitor (A). Right panel is the enlarged region of the box in the left panel. Residue specific assignment of backbone 1H and 15N frequencies is shown with residue name
and sequence number. (C) Secondary structure analysis of pGyrB. Box indicates helical structures. Arrow indicates strands and line indicates loops. Secondary structural
elements for free pGyrB derived from NMR study and eGyrB derived from X-ray structures (PDB ids 1EI1 and 4PRX) are shown in black and red, respectively. The inhibitor-
bound pGyrB has the same secondary structural elements as free pGyrB. The sequence alignment was conducted using ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
The different residues between eGyrB and pGyrB are highlighted in red. (D) Homology model of pGyrB. A model was built using structure of GyrB of E. coli as a template. Left
panel is the crystal structure of eGyrB (PDB id 1EI1). The ADPNP is show in sticks. Middle panel is surface representation of the eGyrB-ADP complex. The right panel is the
model of pGyrB.
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Fig. 4. Residues involved in protein and inhibitor interactions. (A) Plot of CSP as a function of residue number. (B) Difference of Ca chemical shifts in the absence and presence
of the inhibitor. The chemical shift dereference DCa was plotted against residue number. DCa = DCa (free) – DCa (inhibitor). (C) Mapping of affected residues on the pGyrB
model. Residues with CSP more than 0.3 ppm, between 0.2 and 0.3 ppm and between 0.1 and 0.2 ppm are labeled in red, brown and yellow, respectively. The loop between a3
and a4 is shown in blue. (D) Model of pGyrB and inhibitor complex. Left panel is the model of the pGyrB and inhibitor complex, which was based on the structure of ParE-
inhibitor complex (PDB id 4LP0). Dashed lines indicate protein-inhibitor NOEs observed in the NOE experiment. The color code is similar to Fig. 4C. Residues with
unambiguous NOEs with the inhibitor are highlighted with boxes. Middle panel is the structure of the inhibitor used in this study. Carbons with unambiguous assignments
are labeled. Right panel contains select strips of the NOESY-TROSY spectrum. The resonances that may arise from incomplete deuteration or ambiguous assignments of the
inhibitor are labeled with question marks. The NOESY-TROSY spectrum was collected using a 13C/15N/2H-labeled pGyrB and inhibitor at a molar ratio of 1:2.
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C58–I65), b2 (residues S70–N76), b3 (residues E131–R138), b4
(residues K141–H148), b5 (residues L156–T162), b6 (residues
S165–F171), b7 (residues V202–D208) and b8 (residues K213–E220)
and five a helices including a1 (residues L18–M27), a2 (residues
T36–A55) a3 (residues A92–T98), a4 (residues V122–L128) and
a5 (residues W185–L198) present in the pGyrB. The pGyrB shares
very high sequence homology (more than 75% sequence identity)
with GyrB of the E. coli (eGyrB). The secondary structures of
pGyrB derived from NMR data are similar to X-ray structure
of eGyrB, except that there is a short helix present at the
N-terminus of eGyrB, and the lengths of a1, a2, b1, a4, b3, b5,
b6, and b8 are slightly different (Fig. 3C). There are several residues
that are different between these two proteins (Fig. 3C). Although
the difference did not alter the structure of pGyrB, it may affect
inhibitor binding because some of different residues are at the
inhibitor binding regions (Fig. 3C). A homology model of pGyrB
was built using the SWISS-MODEL server (Fig. 3D) using the
X-ray structure of eGyrB bound with adenylyl-imidodiphosphate
(ADPNP) as a template [2,28]. Long-range NOEs of residues in the
b-strands of pGyrB were observed, which supports the homology
model (data not shown).3.4. The bis-pyridylurea inhibitor binds to the ATP binding pocket
To determine which residues were affected by inhibitor binding
to pGyrB, CSP caused by inhibitor binding was plotted against resi-
due number (Fig. 4A). As the chemical shifts of amide and amide
protons are sensitive to the environment, residues showing signif-
icant CSP might be involved in inhibitor binding. It was clear that
those residues from the a2, b2, b6, the loop between b2 and a3,
a3 and a4 were important for inhibitor interaction (Fig. 4A).
Whether the inhibitor could cause structural changes on pGyrB
was investigated by analyzing the changes of the Ca chemical
shifts that are sensitive to the secondary structures. Although sev-
eral residues showed changes in the Ca chemical shifts (Fig. 4B),
the overall structure of pGyrB was not altered as analyzed by
TALOS+ (Fig. 3). The residues from a2 including 44–52 are affected
significantly in the presence of the inhibitor, suggesting that they
are critical for inhibitor binding. This result may also explain the
high quality HNCACB experiment obtained for the complex
because the inhibitor can affect the chemical environments of Ca
and Cb carbons. Residues showing CSPs were mapped to the
homology model of pGyrB (Fig. 4C). Compared with the X-ray
structure of the ParE-inhibitor complex, the inhibitor also binds
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dues and inhibitor were also observed and the orientation of the
inhibitor in pGyrB is similar to the one in ParE of Streptococcus
pneumonia (S. pn).
3.5. Backbone relaxation analysis of pGyrB and its complex
Backbone relaxation data T1, T2 and hetNOE revealed the
dynamic properties of both free and inhibitor bound pGyrB
(Fig. 5). Compared with complex, fewer residues of free pGyrB
were used for analysis because the peaks are too weak to be accu-
rately analyzed. Surprisingly, there is no significant change
observed for these relaxation parameters in the absence and pres-
ence of the inhibitor. The N-terminal 25 residues and the
C-terminal 5 residues are flexible in the absence and presence
the inhibitor, which is characterized with low T1 and hetNOE values
and high T2 values (Fig. 5). The average T1 values excluding both
N- and C-terminal residues and the loop between a3 and a4 for
free pGyrB and complex are 1.43 s and 1.48 s, respectively. The
average T2 values are 37.7 and 37.2 ms, respectively. The loop a3
and a4 compassing residues 100–120 is flexible for both free
pGyrB and complex, suggesting that the loop is not involved in
the molecular interaction with this inhibitor. The hetNOE values
of other residues are higher than 0.82 that is expected for NH
groups in a grid globular protein [26], indicating that these resi-
dues are rigid in solution. Further dynamic study in other time
scales or protein side chain relaxation study will be helpful for
understanding the effect of inhibitor on GyrB dynamics.
4. Discussion
Due to the bacterial resistance to antibiotics, there is a great
need to develop novel antibacterial agents. The rate-limiting stepsFig. 5. 15N relaxation parameters for pGyrB in free (s) and inhibitor bound forms (N). Un
be quantified. The relaxation experiments were collected using a sample that conta
bis-pyridylurea inhibitor.in the antibacterial discovery process are twofold [29]. First, it is
important to select a target that is not prone to resistance develop-
ment and second, it is important to increase chemistry diversity to
overcome the barriers to bacterial entry [29]. Bacterial type II
topoisomerases have been proven to be a good target for antibac-
terial development due to their high sequence homology among
the pathogenic bacteria and low homology with eukaryotes [5,7].
Structure-based drug design has been an important tool in the
development of these novel inhibitors such as tricyclic GyrB/ParE
inhibitors and azaindole class of antibacterial agents [7,10,30].
Understanding protein and inhibitor interaction is important in
drug development. In this study, we carried out NMR studies on
the pGyrB. It is interesting that the assignment for the free pGyrB
was challenging due to the protein stability and low signal sensi-
tivity (Fig. 1B), which might be the reason that there is no struc-
tural information available for both ParE and GyrB from
P. aeruginosa, an extremely important Gram-negative strain with
high pathogenicity. In the presence of the inhibitor that binds to
pGyrB with a KD of 54.6 nM, the protein stability was improved
(Fig. 2A) and we obtained backbone resonance assignments for
both free and inhibitor bound forms of pGyrB (Fig. 3). The sec-
ondary structural elements of pGyrB in solution were determined
based on the assignment (Fig. 3). Although the inhibitor binds to
pGyrB with an affinity in nanomolar range, there was no significant
secondary structural change observed for pGyrB upon inhibitor
binding. Further relaxation results also demonstrated that the
backbone dynamic of pGyrB was not changed dramatically
(Fig. 5). It has been noted that our 3D spectra and relaxation data
suggest that the side chain dynamics of residues in the ATP binding
pocket might be important for ligand binding. In the presence of
the inhibitor, the backbone amide dynamics of pGyrB were not
affected significantly, while the side chain dynamics was influ-
enced (Figs. 1B and 2A). These results imply that careful proteinanalyzed residues include prolines and the ones that are overlapped or too weak to
ined 0.6 mM 13C/15N/2H-labeled pGyrB in the absence and presence of 1.2 mM
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because the binding affinities between the inhibitor and eGyrB/
ParE might be different from pGyrB due to the difference of resi-
dues in the ATP binding pocket. Our study on the ParE of S. pn
showed that swapping a single residue with a corresponding resi-
due in P. aeruginosa in the ATP binding pocket can affected inhibi-
tor binding affinity (Kang et al., unpublished data). Our study also
confirmed that the loop between a3 and a4 of pGyrB was not
involved in inhibitor binding because there were no CSP observed
and dynamic changes were minor in the presence of the inhibitor
(Fig. 5).
The inhibitor used in this study is a pyridylurea scaffold derived
from fragment-based drug design and is ATP competitive [21]. Its
activity against gram-negative strains such as E. coli and gram-
positive strains was investigated in detail [21]. X-ray crystal struc-
ture revealed that D78 of b2 and T172 of b6 from ParE of S. pn
formed hydrogen bonds with the inhibitor. R81 and M83 from
S. pn ParE from the loop between b2 and a3 were shown to interact
with the inhibitor [21]. We carried out biophysical characterization
for the molecular interaction between pGyrB and the inhibitor
(Figs. 1 and 2). Based on the backbone resonance assignment, the
CSP caused by inhibitor binding was investigated in this study.
Residues from b2 (D75), b6 (E168 and V169), loop between b2
and a3, and a3 were shown to be important for inhibitor binding
(Fig. 4). Residues exhibited CSP with more than 0.2 ppm upon inhi-
bitor binding were localized at the ATP binding pocket (Fig. 4).
NOEs between pGyrB and the inhibitor were observed (Fig. 4),
which further confirmed the residues that are important for inhibi-
tor binding. Our results provide direct evidence to show that the
bis-pyridylurea inhibitor binds to the ATP binding pocket of
pGyrB, which is similar to the ParE of S. pn. These results will be
useful to understand protein and inhibitor interactions, which will
be helpful in antibacterial drug development. Although it will be
useful to carry out further studies to understand protein dynamic
in other time scales, this study provides an example to show that
inhibitors or ligands can facilitate structural studies of proteins
by improving spectral quality.
In summary, we purified pGyrB and conducted structural stud-
ies and its interaction with a bis-pyridylurea inhibitor. This inhibi-
tor binds to pGyrB with a KD of 54.6 nM and could improve its
thermal stability. Secondary structures of pGyrB were defined
and inhibitor did not cause significant conformational changes.
CSP and NOE analysis demonstrate that the inhibitor binds to the
ATP binding pocket.
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